Targeted Diseases

Algernon Pharmaceuticals has developed data that supports the advancement of up to 11 drug candidates into phase II trials in the areas of non–alcoholic steatohepatitis (NASH), chronic kidney disease (CKD) and inflammatory bowel disease (IBD).

Non–alcoholic Steatohepatitis
More about NASH
Chronic Kidney Disease
More about CKD
Inflammatory Bowel Disease
More about IBD